A Transgenic Mouse Prostate Cancer Model

Adams JM and Cory S. (1991). Transgenic models of tumor development. Science 254: 1161-1167.

Bauer JJ , Sesterhenn IA , Mostofi KF , Mcleod DG , Srivastava S. , and Moul JW (1995). P53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res. 1(11): 1295-1300.

Brinster RL , Chen HY , Messing A. , Van Dyke T. , Levine AJ , and Palmiter RD (1984). Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 37: 367-379.

DeCaprio JA , Ludlow JW , Figge J. , Shew J.-Y. , Huang C.-M. , Lee W.-H. , Marsilio E. , Paucha E. , and Livingston DM (1988). SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 17: 275-283.

Eastham JA , Stapleton A. , Gousse AE , Timme TL , Yang G. , Slawin KM , Wheeler TM , Scardino PT , and Thompson TC (1995). Association of p53 mutations with metastatic prostate cancer. Clin. Cancer Res. 1(10): 1111-1118.

Greenberg NM , DeMayo F. , Finegold MJ , Medina D. , Tilley WD , Aspinall JO , Cunha GR , Donjacour AA , Matusik RJ , and Rosen JM (1995). Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92: 3439-3443.

Greenberg NM , DeMayo FJ , Sheppard PC , Barrios R. , Lebovitz R. , Finegold M. , Angelopolou R. , Dodd JG , Duckworth ML , Rosen JM , and Matusik RJ (1994). The rat probasin gene promoter directs hormonally- and developmentally-regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol. Endocrinol. 8: 230-239.

Hall MC , Navone NM , Troncoso P. , Pollack A. , Zagars GK , Voneschenbach AC , Conti CJ , and Chung L. (1995). Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45(3): 470-475.

Hanahan D. (1985). Heritable formation of pancreatic β-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes . Nature (London) 315: 115-122.

Heidenberg HB , Sesterhenn IA , Gaddipati JP , Weghorst CM , Buzard GS , Moul JW , and Srivastava S. (1995). Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 154(2, Pt. 1): 414-421.

Isaacs WB , Bova GS , Morton RA , Bussemakers MJ , Brooks JD , and Ewing CM (1994). Molecular biology of prostate cancer. Semin. Oncol. 21 (5): 514-521.

Ittmann MM and Wieczorek R. (1996). Alterations of the retinoblastoma gene in clinically localized, stage b prostate adenocarcinomas. Hum. Pathol. 27(1): 28-34.

Konishi N. , Hiasa Y. , Tsuzuki T. , Matsuda H. , Tao M. , Nakamura M. , Naito H. , Kitahori Y. , Shiraishi T. , Yatani R. , Shimazaki J. , and Lin JC (1996). Detection of rb, p16/cdkn2 and p15(ink4b) gene alterations with immunohistochemical studies in human prostate carcinomas . Int. J. Oncol. 8(1): 107-112.

Kubota Y. , Shuin T. , Uemura H. , Fujinami K. , Miyamoto H. , Torigoe S. , Dobashi Y. , Kitamura H. , Iwasaki Y. , Danenberg K. , and Danenberg PV (1995). Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 27(1): 18-24.

Lane DP and Crawford LV (1979). T-antigen is bound to host proteins in SV-40 transformed cells. Nature (London) 278: 261-263.

Linzer DIH and Levine AJ (1979). Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17: 43-52.

Maroulakou IG , Anver M. , Garrett L. , and Green JE (1994). Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. USA 91: 11236-11240.

Palmiter RD and Brinster RL (1985). Transgenic mice. Cell 41: 343-345.

Sandgren EP , Quaife CJ , Pinkert CA , Palmiter RD , and Brinster RL (1989). Oncogene-induced liver neoplasia in transgenic mice. Oncogene 4(6): 715-724.

Sarkar FH , Sakr W. , Li YW , Macoska J. , Ball DE , and Crissman JD (1992). Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas. Prostate 21(2): 145-152.

Yang G. , Stapleton A. , Wheeler TM , Truong LD , Timme TL , Scardino PT , and Thompson TC (1996). Clustered p53 immunostaining-A novel pattern associated with prostate cancer progression. Clin. Cancer Res. 2(2): 399-401.